HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Breast Neoplasms
/ drug therapy
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Female
Gene Expression
Humans
Lapatinib
Middle Aged
Molecular Targeted Therapy
/ methods
Neoadjuvant Therapy
Neoplasm Staging
Prognosis
Receptor, ErbB-2
/ antagonists & inhibitors
Reproducibility of Results
Survival Analysis
Treatment Outcome
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
received:
01
11
2018
revised:
06
02
2019
accepted:
26
03
2019
pubmed:
1
5
2019
medline:
11
8
2020
entrez:
1
5
2019
Statut:
ppublish
Résumé
Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy. A research-based PAM50 assay was applied in 422 HER2-positive tumors from five II-III clinical trials (SOLTI-PAMELA, TBCRC023, TBCRC006, PER-ELISA, EGF104090). In SOLTI-PAMELA, TBCRC023, TBCRC006, and PER-ELISA, all patients had early disease and were treated with neoadjuvant lapatinib or pertuzumab plus trastuzumab for 12-24 weeks. Primary outcome was pathological complete response (pCR). In EGF104900, 296 women with advanced disease were randomized to receive either lapatinib alone or lapatinib plus trastuzumab. Progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) were evaluated. A total of 305 patients with early and 117 patients with advanced HER2-positive disease were analyzed. In early disease, HER2-E represented 83.8% and 44.7% of ERBB2-high and ERBB2-low tumors, respectively. Following lapatinib and trastuzumab, the HER2-E and ERBB2 (HER2-E/ERBB2)-high group showed a higher pCR rate compared to the rest (44.5%, 95% confidence interval [CI] = 35.4% to 53.9% vs 11.6%, 95% CI = 6.9% to 18.0%; adjusted odds ratio [OR] = 6.05, 95% CI = 3.10 to 11.80, P < .001). Similar findings were observed with neoadjuvant trastuzumab and pertuzumab (pCR rate of 66.7% in HER2-E/ERBB2-high, 95% CI = 22.3% to 95.7% vs 14.7% in others, 95% CI = 4.9% to 31.1%; adjusted OR = 11.60, 95% CI = 1.66 to 81.10, P = .01). In the advanced setting, the HER2-E/ERBB2-high group was independently associated with longer PFS (hazard ratio [HR] = 0.52, 95% CI = 0.35 to 0.79, P < .001); higher ORR (16.3%, 95% CI = 8.9% to 26.2% vs 3.7%, 95% CI = 0.8% to 10.3%, P = .02); and longer OS (HR = 0.66, 95% CI = 0.44 to 0.97, P = .01). Combining HER2-E subtype and ERBB2 mRNA into a single assay identifies tumors with high responsiveness to HER2-targeted therapy. This biomarker could help de-escalate chemotherapy in approximately 40% of patients with HER2-positive breast cancer.
Sections du résumé
BACKGROUND
Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy.
METHODS
A research-based PAM50 assay was applied in 422 HER2-positive tumors from five II-III clinical trials (SOLTI-PAMELA, TBCRC023, TBCRC006, PER-ELISA, EGF104090). In SOLTI-PAMELA, TBCRC023, TBCRC006, and PER-ELISA, all patients had early disease and were treated with neoadjuvant lapatinib or pertuzumab plus trastuzumab for 12-24 weeks. Primary outcome was pathological complete response (pCR). In EGF104900, 296 women with advanced disease were randomized to receive either lapatinib alone or lapatinib plus trastuzumab. Progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) were evaluated.
RESULTS
A total of 305 patients with early and 117 patients with advanced HER2-positive disease were analyzed. In early disease, HER2-E represented 83.8% and 44.7% of ERBB2-high and ERBB2-low tumors, respectively. Following lapatinib and trastuzumab, the HER2-E and ERBB2 (HER2-E/ERBB2)-high group showed a higher pCR rate compared to the rest (44.5%, 95% confidence interval [CI] = 35.4% to 53.9% vs 11.6%, 95% CI = 6.9% to 18.0%; adjusted odds ratio [OR] = 6.05, 95% CI = 3.10 to 11.80, P < .001). Similar findings were observed with neoadjuvant trastuzumab and pertuzumab (pCR rate of 66.7% in HER2-E/ERBB2-high, 95% CI = 22.3% to 95.7% vs 14.7% in others, 95% CI = 4.9% to 31.1%; adjusted OR = 11.60, 95% CI = 1.66 to 81.10, P = .01). In the advanced setting, the HER2-E/ERBB2-high group was independently associated with longer PFS (hazard ratio [HR] = 0.52, 95% CI = 0.35 to 0.79, P < .001); higher ORR (16.3%, 95% CI = 8.9% to 26.2% vs 3.7%, 95% CI = 0.8% to 10.3%, P = .02); and longer OS (HR = 0.66, 95% CI = 0.44 to 0.97, P = .01).
CONCLUSIONS
Combining HER2-E subtype and ERBB2 mRNA into a single assay identifies tumors with high responsiveness to HER2-targeted therapy. This biomarker could help de-escalate chemotherapy in approximately 40% of patients with HER2-positive breast cancer.
Identifiants
pubmed: 31037288
pii: 5475264
doi: 10.1093/jnci/djz042
pmc: PMC7850037
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Biomarkers, Tumor
0
Lapatinib
0VUA21238F
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
pertuzumab
K16AIQ8CTM
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-54Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA186784
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA058183
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
J Clin Oncol. 2012 Jul 20;30(21):2585-92
pubmed: 22689807
Breast Cancer Res. 2017 Feb 9;19(1):16
pubmed: 28183321
Cancer Treat Rev. 2018 Jun;67:63-70
pubmed: 29763779
JAMA Oncol. 2016 Oct 01;2(10):1287-1294
pubmed: 27281556
N Engl J Med. 2015 Jan 8;372(2):134-41
pubmed: 25564897
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
Lancet Oncol. 2017 Apr;18(4):545-554
pubmed: 28238593
BMC Med. 2015 Dec 18;13:303
pubmed: 26684470
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
Clin Cancer Res. 2012 Dec 15;18(24):6784-91
pubmed: 23092874
J Natl Cancer Inst. 2014 Aug 19;106(8):
pubmed: 25139534
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
J Clin Oncol. 2010 Mar 1;28(7):1124-30
pubmed: 20124187
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
J Clin Oncol. 2013 May 10;31(14):1726-31
pubmed: 23569315
Ann Oncol. 2019 Jun 1;30(6):921-926
pubmed: 30778520
Lancet Oncol. 2013 Nov;14(12):1183-92
pubmed: 24095300
J Clin Oncol. 2012 Jun 1;30(16):1989-95
pubmed: 22493419
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
BMC Cancer. 2014 Mar 13;14:177
pubmed: 24625003
Clin Cancer Res. 2016 Feb 1;22(3):560-6
pubmed: 26152740
Clin Cancer Res. 2014 Jan 15;20(2):511-21
pubmed: 24443618
BMC Med. 2019 Jan 9;17(1):8
pubmed: 30621698
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
J Clin Oncol. 2016 Feb 20;34(6):542-9
pubmed: 26527775
Clin Cancer Res. 2020 Feb 15;26(4):821-827
pubmed: 31662331
Ann Oncol. 2018 Mar 1;29(3):646-653
pubmed: 29253081
Breast. 2017 Aug;34 Suppl 1:S19-S26
pubmed: 28687441
Mol Oncol. 2011 Feb;5(1):5-23
pubmed: 21147047